Chris Lehman’s Post

March 04, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Akero’s $300 Million Public Offering BridgeBio’s $250 Million Public Offering Arcutis’s $173 Million Public Offering…More More Revance’s $100 Million Public Offering Nocion’s $62 Million Series B… More Armata’s $35 Million Debt Financing Nektar’s $30 Million Private Placement BioVie’s $21 Million Public Offering C4 Therapeutics $16 Million Upfront Fortress and Cyprium’s $4.1 Million NINDS Grant Bone’s $2 Million Public Offering

Calidi Biotherapeutics, a biotech company developing targeted immunotherapies, has successfully priced its public offering for 15,197,500 shares of common stock or pre-funded warrants. The offering also includes Series A, B, and C Common Warrants, each comprising one share of common stock and a corresponding warrant, with a combined effective price of $0.40, generating approximately $6.1 million in gross proceeds. Ladenburg Thalmann & Co. Inc. is the sole placement agent for the offering. The proceeds from the offering will primarily be used for working capital, general corporate purposes, and pre-clinical and clinical trials. The common warrants have an exercise price of $0.60 per share and will expire at various intervals from the issuance date. The offering is made through a registration statement filed with the Securities and Exchange Commission (SEC) and became effective on April 15, 2024. Both preliminary and final prospectuses are available on the SEC's website. #CalidiBiotherapeutics #Immunotherapy #Biotech #StockOffering #SEC #LadenburgThalmann Steve Thesing

Exciting update! Venkat Nelabhotla, the CEO at Vyome Therapeutics, Inc., is going to be a keynote speaker at our 7th Annual Drug Discovery Summit, Princeton,NJ. Grab your spot now by reaching out to- Sid@alcor-wealth.com. Be a part of this awesome summit where we dive deep into the world of drug discovery. #ADDP #DrugDiscovery #Innovation #Summit2024 #biotechnology Secure your spot and let's make this summit a blast! 🚀

Opyl has partnered with L39 Capital Pty Ltd to launch an AI Biotech Fund. This fund will leverage our proprietary TrialKey technology, targeting $100M in AUM within 36 months. TrialKey’s predictive power will help us identify high-return biotech stocks, initially focusing on the US and Australia with over 200 annual inflection points. Book a demo:https://lnkd.in/grvHkpXN Marketing and investor enquiries: bernice.averion@opyl.ai  #aiinbiotech #clinicaltrials #opyl #investment #biotech #biopharma #medtech #pharmaceuticals #healthcare #softwaredevelopment #asx #investing"

Exclusive: Prolific life sciences investor The Column Group has raised more than $400 million for its 10th fund, and the Bay Area firm will take a different approach this time around. Rather than backing platform biotechs, TCG Labs will bankroll single-asset biologics companies based on ideas out of its network built up over the past 17 years. The firm will work with scientists at TCG Labs-Soleil, an R&D hub led by NGM Biopharmaceuticals founder Jin-Long Chen, to test the assets through Phase I or II testing, at which point it will then sell the asset to pharma. “You don’t build 10 good teams. You build one great team,” Chen said of keeping all R&D in one hub at Soleil. “We keep the laboratory going, just like Genentech and Amgen were able to survive and build some of the industry’s best drug-hunting places instead of the typical biotech company getting bought after five to 10 years, and the whole team dissolves,” managing partner Peter Svennilson said in an interview with Endpoints News. #biotech #venturecapital #biologics #startups #drugdevelopment #drugdiscovery

🚨 Aerovate Therapeutics Stock Downgraded 🚨 Aerovate Therapeutics stock has been downgraded by BTIG following a setback in the AV-101 trial. Mixed analyst views are emerging, making future pivotal readouts crucial for investors. 📉🔍 #Biotech #Investing #StockMarket #Healthcare #Pharma #ClinicalTrials #InvestmentNews #StockUpdate https://lnkd.in/dnkX2JEe

Are we finally out of the Biotech Winter? Last week saw 5 Biotech's with successful rounds of more than $100 million. 1. Freenome $254M 2. BioAge Labs $170M 3. Latigo Biotherapeutics, Inc. $135M 4. ProfoundBio $112M 5. Alys Pharmaceuticals $100M The AI sector also had a number of successful deals last week, its starting to feel a bit like 2021 again! We are all hoping for a Dream of Spring (some of us still want the Winds of Winter though). #biotech #investment #gameofthrones

🔬 Exciting Breakthrough in Biotech! Tierra Biosciences has just announced the successful closure of their $11.4M Series A funding round, led by Material Impact with contributions from notable investors like Prosus Ventures, In-Q-Tel, Hillspire, Freeflow Ventures, Creative Ventures, and Social Capital. This significant investment marks a milestone in the advancement of protein synthesis technology. Tierra Biosciences, renowned for its pioneering cell-free protein production platform, is revolutionizing the way we approach protein engineering. By leveraging predictive AI and high-throughput technology, they provide rapid access to custom proteins, accelerating discovery and development processes in various industries, including pharmaceuticals, agriculture, and more. Their innovative approach, which combines the power of AI language models with high-throughput cell-free platforms, is pushing the boundaries of protein engineering. Tierra’s technology is not just enhancing protein synthesis; it’s reshaping entire industries and promising a new era of bioeconomy innovation. With this new funding, Tierra Biosciences is set to expand its reach and continue its mission to democratize access to engineered proteins, driving significant advancements in human health, environmental sustainability, and global food security. A big congratulations to the Tierra team on this achievement! #seriesa #biotech #venturecapital

Thoughts on this? >> Alzheimer's biotech Asceneuron raises $100M to see if it can compete with Lilly, Biogen on tau >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

Revolutionising Drug Discovery: Innovations in Biotech The pharmaceutical landscape is evolving rapidly, driven by technological advancements and innovative approaches. One of the key challenges facing the industry has been the lack of druggable targets for diseases affecting large populations. However, emerging technologies are reshaping drug discovery. This week, we profile 3 startups driving innovation in biotech: Vivodyne, Cytonus Therapeutics and Zafrens. Read more: https://lnkd.in/djAG4DQY Get innovation insights from The FutureList weekly. Subscribe to our newsletter here: https://bit.ly/3DVZexv #biotech #biotechnology #medtech #innovation #drugdiscovery